CANTON, Mass., April 30, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it will present new Apligraf® comparative effectiveness data and chronic wound burden of illness economic analyses at the Symposium of Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Meeting (SAWC Spring/WHS) held May 1-5, 2013 in Denver, Colorado. Organogenesis is also supporting a WHS research award program and will feature Apligraf at booth #707.
Apligraf is a living, cell-based product for the treatment of chronic wounds, and is the only product with FDA approval to treat both venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). Apligraf consists of keratinocytes, fibroblasts and collagen, which play important roles in wound healing. By delivering these components directly to a wound, Apligraf induces the body to generate the tissue necessary to heal.
In an oral presentation titled, "A Retrospective Analysis of a Bilayered Living Cellular Construct and a Porcine Collagen Wound Dressing for the Treatment of Venous Leg Ulcers in a Real World Setting," Michael L. Sabolinski, MD, will unveil new data from a retrospective comparative effectiveness analysis of Apligraf and a non-interactive collagen wound dressing in the treatment of VLUs. A total of 1,489 patients were included in the analysis, which was conducted on treatment records collected over a three-year period from the WoundExpert (Net Health Systems Inc.) electronic medical record database. This data represents the largest real-world comparative effectiveness analysis conducted with Apligraf.